Abstract
Statins have multiple actions, independent of their classical effects on lipoproteins. The data about the effects of statins on insulin resistance is controversial. This study was designed to search the statin effects on nondiabetic dyslipidemic patients. Thirty-five (17 male, 18 female) consecutive dyslipidemic patients 54.25±8.81 yr were enrolled in the study. After a standard follow-up period of lifestyle modification, the patients were given fluvastatin 40 mg/d for 8 wk. Serum analyses were done both before and after treatment. Insulin resistance was assessed by homeostasis assessment model (HOMA). Fasting plasma triglyceride, total and LDL cholesterol, fasting insulin, and HOMA index were significantly reduced and HDL cholesterol was improved after fluvastatin treatment. HOMA-IR was not correlated with triglycerides, LDL, HDL, or total cholesterol levels. The same situation was present for both fasting plasma insulin and fasting plasma glucose levels. Also age was not associated with HOMA-IR and fasting plasma insulin levels. As a conclusion, the present study indicates that fluvastatin treatment improves insulin resistance in dyslipidemic patients who do not have diabetes or impaired fasting glucose. Also, the effect of fluvastatin on insulin resistance is not associated with the lowering of triglycerides. The latter finding indicates that the effect of statins on insulin sensitivity may not be related with the lowering of triglycerides in dyslipidemic patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Downs, J. R., Clearfield, M., Weis, S., et al. (1998). JAMA 279, 1615–1622.
The Scandinavian Simvastatin Survival Study (4S). (1994). Lancet 344, 1383–1389.
Shepherd, J., Cobbe, S. M., Ford, I., et al. (1995). N. Engl. J. Med. 333, 1301–1307.
Freeman, D. J., Norrie, J., Sattar, N., et al. (2001). Circulation 103, 357–362.
Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). JAMA 285, 2508–2509.
Eschwege, E., Richard, J. L., Thibult, N., et al. (1985). Horm. Metab. Res. 15, 41–46.
Despr’s, J. P., Lamarche, B., Mauriege, P., et al. (1996). N. Engl. J. Med. 334, 952–957.
Welborn, T. A. and Weane, K. (1974). Diabetes Care 2, 154–160.
Pyorala, K., Savolainen, E., Kaukola, S., and Haapakoski, J. (1985). Acta Med. Scand. 701, 38–52.
Pontrelli, L., Parris, W., Adeli, K., and Cheung, R. C. (2002). Metabolism 51(3), 334–342.
Malik, J., Melenovsky, V., Wichterle, D., et al. (2001). Cardiovasc. Res. 52(2), 290–298.
Paolisso, G., Barbagallo, M., Petrella, G., et al. (2000). Atherosclerosis 150(1), 121–127.
Orhvall, M., Lithell, H., Johansson, J., and Vessby, B. (1995). Metabolism 44, 212–217.
Farrer, M., Winocur, P. H., Evans, K., et al. (1994). Diabetes Res. Clin. Pract. 23, 111–119.
Le Roith, D. and Zick, Y. (2001). Diabetes Care 24, 588–597.
Rigalleau, V., Beylot, M., Pachiaudi, C., Guillot, C., Deleris, G., and Gin, H. (1998). Am. J. Physiol. 275(4 Pt 1), E641-E648.
Mingrone, G., Henriksen, F. L., Greco, A. V., et al. (1999). Diabetes 48(6), 1258–1263.
Randle, P. J., Garland, P. B., Hales, C. N., and Newsholme, F. A. (1963). Lancet 1, 785–789.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). JAMA 285(19), 2486–2497.
Friedwald, W. T., Levy, R., and Fredrickson, D. S. (1978). Clin. Chem. 18, 499–502.
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C. (1985). Diabetologia 28, 412–419.
Emoto, M., Nishizawa, Y., Maekawa, K., et al. (1999). Diabetes Care 22, 818–822.
Bonora, E., Forementini, G., Calcaterra, F., et al. (2002). Diabetes Care 25, 1135–1141.
Katsuki, A., Sumida, Y., Gabazza, E. C., et al. (2001). Diabetes Care 24, 362–365.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sonmez, A., Baykal, Y., Kilic, M. et al. Fluvastatin improves insulin resistance in nondiabetic dyslpidemic patients. Endocr 22, 151–153 (2003). https://doi.org/10.1385/ENDO:22:2:151
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:22:2:151